Focus on the Locus! (Ceruleus, That Is, in Alzheimer’s Disease)
disease (Mann et al., 1980; Bondareff et al., 1982; Haglund et al., 2006). Tau pathology also occurs in LC
Upcoming Webinars
No Upcoming Webinars AvailableALL WEBINARS
129 RESULTS
You searched Skovronsky et al., 1998
Sort By:
- Most Recent
- Most Commented
- Most Relevant
Intracellular Aβ in Alzheimer's Disease
in culture (Skovronsky et al., 1998). Recently, Aβ42 accumulation was reported both in neurons in the
Cholesterol and Alzheimer's—Charging Fast But Still at a Distance from Solid Answers
paper by Fassbinder (Fassbinder et al., 2002) on no change in Aβ after statin treatment. Tobias Hartmann
Can We (Should We?) Develop “Smart Drugs” to Stave Off Age-Related Memory Loss?
al., 2002; Grön et al., 2005; Chuah and Chee, 2008; FitzGerald et al., 2008). The Alzforum set out to
Resolving Controversies on the Path to AD Therapeutics
pharma picks them up for human translation (Prinz et al., 2011). Hyped coverage of such publications can
Webinar: Pathogenic Protein Spread? Let’s Think Again
that propagate may not always cause dysfunction (e.g., Liu et al., 2015). Rather, dysfunction may arise
Meet New Players, Histone Deacetylase and Sirtuin—Will They Help the Cell Cycle, DNA Repair, and Gene Expression Break Into Alzheimerology’s Major League?
important roles of protein acetylation. I am also referring to this month’s paper by Creppe et al., 2009 on
Untapped Resource? New Study to Boost Acceptance of CSF Analysis
mild cognitive impairment to AD (see Hansson et al., 2006; Fagan et al., 2006; Shaw et al., 2009; and
Cerebrometabolic Deficiency in Alzheimer's Disease
cholinergic mechanisms (Ragozzini et al., 1998). Gabrielle Strobel: That is interesting. I look forward to
Differential Neuronal Vulnerability
disease, the mutated protein also disturbs function of skin cells in patients (according to Seo et al.,
Finding NIH Support for Drug Discovery and Development for Neurodegenerative Diseases
Searching for the wherewithal to push on with your work on a promising new Alzheimer therapy? The NIH offers funding for research support at every step of the process, from early drug discovery right through to phase 3 clinical trials, if you know where t
Targeting Tumor Necrosis Factor—A Therapeutic Strategy for AD
inhibitor, which blocks its translocation: dehydroxymethylepoxyquinomicin (Kubota et al., 2007). Lovastatin
Microdissection and Microarrays: Analyzing Selective Cell Vulnerability
Sweden, recently reported on selective cell vulnerability in motor neuron diseases (Hedlund et al., 2010).
Probing PPARγ? Agonists: Could Diabetes Drugs Treat Alzheimer's Disease?
Jiang et al., 1998), together with the commercial availability of PPARγ agonists, has raised interest in
Clearing the Fog Around Aβ Oligomers
concentrations (see ARF related news story and Lambert et al., 1998). Soon, numerous other labs fingered Aβ
Have a topic idea for a webinar? We would love to hear it. Send an email to webinars [at] alzforum [dot] org.
Current Filters
- Keyword: Skovronsky et al., 1998 x